Central Trust Company’s Aldeyra Therapeutics ALDX Stock Holding History

Central Trust Company’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-17	Closed	–	–	1354
2022 Q1	$0	Buy	+17	New	+$68	﹤0.01%	1333

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Central Trust Company's ALDX Position: Q2 2022 in Review

Central Trust Company sold out of Aldeyra Therapeutics (ALDX) in Q2 2022, closing a stake of 17 shares.

Central Trust Company first reported a position in ALDX in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 95 funds tracked by Wall St. Rank hold ALDX as of Q2 2022.

Central Trust Company reported no remaining Aldeyra Therapeutics position as of Q2 2022 after selling out during the quarter.
Central Trust Company sold 17 Aldeyra Therapeutics shares in Q2 2022.
Central Trust Company first reported a position in Aldeyra Therapeutics in Q1 2022 and held it in 1 quarter.
Central Trust Company's Aldeyra Therapeutics position peaked at $0 in Q1 2022.
95 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2022.

Based on Central Trust Company's 13F filing for Q2 2022, filed 9 Aug 2022.